Promising combo tackles tough lung cancer

NCT ID NCT03184571

Completed Disease control Sponsor: BerGenBio ASA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new two-drug combination (bemcentinib plus pembrolizumab) in 99 adults with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or stop them from growing. Participants received both drugs by mouth or IV, and the study measured how many people had a significant tumor response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma of Lung lung adenocarcinoma lung cancer metastatic malignant neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF LUNG LUNG CANCER METASTATIC NSCLC STAGE IV

Contacts and locations

Locations

Christie NHS Hospital Foundation Trust

Manchester, M20 4BX, United Kingdom
Dartmouth-Hitchcock Medical Center (DHMC)

Lebanon, New Hampshire, 03756, United States
Guy's and St Thomas' NHS Foundation Trust

London, SE1 9RT, United Kingdom
Hospital Clinic Barcelona

Barcelona, 08036, Spain
Hospital Teresa Herrera

A Coruña, 15006, Spain
Hospital Universitari Germans Trias i Pujol-ICO

Barcelona, Badalona, 08916, Spain
Hospital Universitario 12 de Octubre, Servicio de oncologia

Madrid, 28041, Spain
Hospital Universitario Fundacion Jimene Diaz

Madrid, 28040, Spain
Hospital Universitario Vall d'Hebron (VHIR)

Barcelona, 08035, Spain
Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain
Medical College of Wisconsin, 9200 W Wisconsin Avenue

Milwaukee, Wisconsin, 53226-3522, United States
Radiumhospitalet, Oslo University Hospital PB

Oslo, 0424, Norway
Servicio de Oncologia Hospital del Mar

Barcelona, 08003, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.